Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell
Safia Safa-Tahar-Henni1,2, Karla Páez Martinez1,2, Verena Gress3
1Laboratory for High Throughput Biology, Montréal, QC, Canada.
Abstract:
Targeted therapeutics for high-risk cancers remain an unmet medical need. Here we report the results of a large-scale screen of over 11,000 molecules for their ability to inhibit the survival and growth in vitro of human leukemic cells from multiple sources including patient samples, de novo generated human leukemia models, and established human leukemic cell lines. The responses of cells from de novo models were most similar to those of patient samples, both of which showed striking differences from the cell-line responses. Analysis of differences in subtype-specific therapeutic vulnerabilities made possible by the scale of this screen enabled the identification of new specific modulators of apoptosis, while also highlighting the complex polypharmacology of anti-leukemic small molecules such as shikonin. These findings introduce a new platform for uncovering new therapeutic options for high-risk human leukemia, in addition to reinforcing the importance of the test sample choice for effective drug discovery.
Insights
This study screened over 11,000 molecules to find new leukemia treatments. Using patient-derived models proved crucial for identifying effective anti-leukemia drugs and understanding their mechanisms.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Targeted therapies for high-risk cancers, particularly leukemia, are urgently needed.
- Current drug discovery often relies on established cell lines, which may not accurately reflect patient responses.
Purpose of the Study:
- To identify novel therapeutic agents for high-risk human leukemia.
- To establish a robust platform for leukemia drug discovery using diverse cell models.
- To investigate subtype-specific vulnerabilities and drug mechanisms.
Main Methods:
- Conducted a large-scale in vitro screen of over 11,000 molecules against human leukemia cells.
- Utilized patient samples, de novo generated leukemia models, and established cell lines for testing.
- Analyzed differential drug responses across various leukemia models.
Main Results:
- Identified specific modulators of apoptosis with anti-leukemic activity.
- Observed that de novo models closely mirrored patient sample responses, unlike established cell lines.
- Highlighted the complex polypharmacology of small molecules like shikonin.
Conclusions:
- The study presents a new platform for discovering therapeutic options for high-risk leukemia.
- Emphasizes the critical importance of using appropriate test samples (patient-derived or de novo models) in drug discovery.
- Findings advance the understanding of leukemia subtype-specific vulnerabilities and drug actions.
More Related Videos
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
